Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Puxitatug samrotecan - AstraZeneca

Next Previous
Drug Profile

Puxitatug samrotecan - AstraZeneca

Alternative Names: AZD-8205

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometrial cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 09 Sep 2025 M.D. Anderson Cancer Center in collaboration with AstraZeneca plans a phase II trial for Adenoid cystic carcinoma (Recurrent, Metastatic disease, Late-stage disease) in the US (IV) in February 2026 (NCT07162480)
  • 01 Aug 2025 Phase-III clinical trials in Endometrial cancer (Recurrent, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (NCT07044336)
  • 01 Aug 2025 AstraZeneca initiates enrolment in a phase III trial for Endometrial cancer (Recurrent, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) NCT07044336)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top